NKTR · ISSUER CIK 906709
NEKTAR THERAPEUTICS
Between Aug 1, 2026 and Oct 29, 2026, 7 NEKTAR THERAPEUTICS insiders reported $0.00 of open-market purchases and $43K of sales on SEC Form 4.
↗7 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$43KInsider selling
−$43KNet open-market
Sep 25, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 202620:29 | Sep 23, 2026 | NKTR | Director | A · Grant | — | +2,000 | 16,417 | +14% | — | ||
| Sep 25, 202620:26 | Sep 23, 2026 | NKTR | Director | A · Grant | — | +2,000 | 22,239 | +10% | — | ||
| Sep 25, 202620:22 | Sep 23, 2026 | NKTR | Director | A · Grant | — | +2,000 | 19,019 | +12% | — | ||
| Sep 25, 202620:20 | Sep 23, 2026 | NKTR | Director | A · Grant | — | +2,000 | 3,904 | +105% | — | ||
| Sep 25, 202620:18 | Sep 23, 2026 | NKTR | Director | A · Grant | — | +2,000 | 4,277 | +88% | — | ||
| Aug 20, 202619:05 | Aug 18, 2026 | NKTR | Chief R&D Officer | S · Sell | $71.98 | −186 | 9,570 | -2% | −$13K | ||
| Aug 20, 202619:03 | Aug 18, 2026 | NKTR | President & CEO, Director | S · Sell | $71.98 | −418 | 54,627 | -1% | −$30K |